OccuLogix Re-Acquires IP Rights to Nonophthalmic Indications for RHEO

OccuLogix announced that, in connection with entering into a supply and co-marketing agreement with Rheogenx Biosciences, OccuLogix has re-acquired its patent, know-how and trademark rights to nonophthalmic indications for RHEO in North America that the company had previously licensed to Rheogenx. The supply and co-marketing agreement secures for PhereSys Therapeutics, Rheogenx's wholly owned subsidiary, a supply of pumps and disposable treatment sets.

MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqKJG0bKbmdG4yJqYotC)